Specialty Pharma Journal Specialty, Precision & Technology
TOKYO and MUNICH and BASKING RIDGE, N.J., Nov. 27, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into an agreement with Roche to collaborate on the development of a new HER2 low companion diagnostic test. Under the terms of the agreement, Roche …
Tag Archives: Daiichi Sankyo
November, 2018
-
21 November
FDA Grants Priority Review to Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukemia
TOKYO, MUNICH and BASKING RIDGE, N.J., Nov. 21, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted Priority Review for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute …
August, 2018
-
30 August
ProLynx and Daiichi Sankyo Announce the Development of Technology for Half-Life Extension of Small Molecules in the Eye
SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) — ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for long-acting intravitreal delivery of small molecules”. In this work, they described a technology to extend the intravitreal half-life of …
-
2 August
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s Quizartinib for Relapsed/Refractory FLT3-ITD AML
Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). “There have …
-
2 August
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab …
May, 2018
-
16 May
Zymeworks and Daiichi Sankyo Expand Immuno-Oncology Collaboration Focused on Bispecific Antibodies
VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and Daiichi Sankyo Company, Limited (Daiichi Sankyo) announced today that they entered into a new license agreement, building upon their 2016 cross-licensing and collaboration agreement. “With a successful track record …
-
9 May
Daiichi Sankyo’s Quizartinib Significantly Prolongs Overall Survival in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations
TOKYO, MUNICH, and BASKING RIDGE, N.J., May 8, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announces that the pivotal QuANTUM-R phase 3 study of single agent quizartinib met its primary endpoint of significantly prolonging overall survival compared to salvage chemotherapy in patients with relapsed/refractory acute myeloid leukemia …
January, 2018
-
18 January
Daiichi-Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer
TOKYO, BASKING RIDGE, N.J. and MUNICH, Jan. 18, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab …
December, 2017
-
13 December
Daiichi Sankyo and Puma Collaborate with Major Cancer Center in HER2-Mutated Cancer
TOKYO, BASKING RIDGE, N.J. & LOS ANGELES–(BUSINESS WIRE)–Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Puma Biotechnology, Inc. (Nasdaq: PBYI) have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER …
October, 2017
-
30 October
Daiichi Sankyo & Glycotope Enter Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing
TOKYO and BASKING RIDGE, N.J., and BERLIN, Oct. 30, 2017 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with …